SYK - Stryker Corporation
A medical technology company specializing in orthopedic implants, surgical equipment, and neurotechnology — a steady compounder in the healthcare devices space.
Finlify Score
30.9 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$307.94
-1.36%
52W Range
$281.00 - $404.87
Market Cap
$117.0B
-1.4%Compared to previous day
2026 Q1 Revenue
$6.0B
-16.1%Changes from last reporting quarter
2026 Q1 EPS
$1.00
Diluted shares
Analyst Rating
35 analysts in latest ratings feed
RSI
46.4
40-70 moderate
2Y Range Position
22%
-24.2% from high / +9.6% from low
Beta
0.78
Relative to market benchmark
MACD
1.41
MACD line -1.29 / signal line -2.70
Fundamental Trend
Growth 14.2Financial Health
Quality 61.1Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID30.9 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $6.0B-16.1% | $7.2B+18.4% | $6.1B+0.6% | $6.0B+2.7% |
| Gross Profit | $3.8B-17.7% | $4.6B+20.1% | $3.9B+0.3% | $3.8B+2.6% |
| Operating Income | $936M-48.1% | $1.8B+58.9% | $1.1B+2.0% | $1.1B+33.0% |
| Net Income | $745M-12.2% | $849M-1.2% | $859M-2.8% | $884M+35.2% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for SYK as of 2026-06-12 is "AVOID", with a Finlify Score of 32.7 out of 100. This appears to be primarily influenced by notably low scores in Relative Strength and Fundamental Trend.
Technical
The low Relative Strength score of 12.2/100 suggests that SYK may have underperformed its peers over recent periods. While Accumulation / Volume appears moderate at 66.4/100, the asset has experienced a -9.7% return over the past 60 days and is currently 19.6% below its 52-week high, indicating potential recent price weakness despite a neutral RSI of 52.9.
Fundamentals
The Fundamental Trend score of 14.2/100 indicates a potential deterioration in underlying business performance or outlook, despite a moderate Financial Quality score of 61.1/100. Valuation metrics appear elevated, with a P/E ratio of 37.1x, a P/B of 6.0x, and a P/S of 4.8x, which may suggest the asset is trading at a premium. The asset does offer a dividend yield of 1.15% and exhibits lower volatility with a Beta of 0.8.
Macro Context
The current macro environment, characterized by elevated inflation (CPI YoY at 4.3%) and higher interest rates (10Y Treasury Yield at 4.5%), may present headwinds for growth-oriented assets like SYK, potentially impacting its valuation multiples. The positive yield spread of 0.4% suggests a normal, albeit tight, yield curve.
Key Risks
- The very low Fundamental Trend score of 14.2/100, coupled with a recent earnings MISS, suggests potential underlying business deterioration or unmet expectations.
- Elevated valuation multiples, including a P/E ratio of 37.1x, P/B of 6.0x, and P/S of 4.8x, may indicate the asset is trading at a premium relative to its current fundamentals.
- The asset's -9.7% return over 60 days and being 19.6% below its 52-week high, alongside a low Relative Strength score of 12.2/100, indicates significant recent price underperformance.